

Table S1. Clinical variables and overall toxicity

Characteristics	N	Overall toxicity		χ^2	p-value	OR	IC _{95%}
		No N (%)	Yes (Grade 1-4) N (%)				
Gender							
Female	52	15 (28.8)	37 (71.2)	0.399	0.528	-	-
Male	49	17 (34.7)	32 (65.3)				
Age diagnosis PS	101	26.5 (18.2-49.3)	28.5 (18.8-41.4)	0.702	0.486	-	-
Family History of Ps							
Yes	52	17 (32.7)	35 (67.3)	0.050	0.822	-	-
No	49	15 (30.6)	34 (69.4)				
Smoking							
Smoker	31	13 (41.9)	18 (58.1)	2.326	0.313	-	-
Non-smoking	49	14 (28.6)	35 (71.4)				
Former Smoker	21	5 (23.8)	16 (76.2)				
Alcoholic drinking							
Drinker	38	16 (42.1)	22 (57.9)	-	0.134	-	-
Non-drinker	61	15 (24.6)	46 (75.4)				
Former Drinker	2	1 (50.0)	1 (50.0)				
Type of Psoriasis							
Plaque	74	27 (36.5)	47 (63.5)	-	0.633*	-	-
Pustular	5	1 (20.0)	4 (80.0)				
Inverse	1	0 (0.0)	1 (100.0)				
Guttate	5	1 (20.0)	4 (80.0)				
Plaque and guttate	12	2 (16.7)	10 (83.3)				
Plaque and inverse	2	0 (0.0)	2 (100.0)				
Plaque and pustular	1	1 (100.0)	0 (0.0)				
Plaque, guttate and inverse	1	0 (0.0)	1 (100.0)				
Localization							
Trunk and limbs							
Yes	93	29 (31.2)	64 (68.8)	-	0.706*	-	-
No	8	3 (37.5)	5 (62.5)				
Scalp and face							
Yes	77	25 (32.5)	52 (67.5)	0.092	0.762	-	-
No	24	7 (29.2)	17 (70.8)				
Nails							
Yes	58	14 (24.1)	44 (75.9)	3.583	0.058	2.24	0.89-5.81
No	43	18 (41.9)	25 (58.1)			1	-
Palmoplantar							
Yes	19	7 (36.8)	12 (63.2)	0.288	0.592	-	-
No	82	25 (30.5)	57 (69.5)				
Flexures							
Yes	28	8 (28.6)	20 (71.4)	0.173	0.677	-	-
No	73	24 (32.9)	49 (67.1)				
Development of PSA							
Yes	31	3 (9.7)	28 (90.3)	10.007	0.002	6.60	2.08-29.44
No	70	29 (41.4)	41 (58.6)			1	-
Comorbidities							
Yes	57	14 (24.6)	43 (75.4)	3.066	0.079	-	-
No	44	18 (40.9)	26 (59.1)				
Age of onset of MTX	101	46.1916.13±	45.3314.25±	-	0.798	-	-
MTX therapy duration (months)	101	14.5 (8.75-23.25)	15.0 (5.0-37.0)	-	0.345	-	-

[illegible]